Cullgen’s Participation in the J.P. Morgan Healthcare Conference

Cullgen's Conference Participation and Development Progress

Cullgen Inc., a consolidated subsidiary of GNI Corporation, will participate in the 44th J.P. Morgan Healthcare Conference held in San Francisco, USA, starting January 12, 2026. This is one of the world’s largest investor conferences in the healthcare industry, and Cullgen has released its latest corporate presentation materials. These materials indicate that the new non-opioid analgesic candidate CG001419 is scheduled to begin Phase 2 clinical trials in Q2 2026, and that the targeted protein degrader development program for inflammatory diseases has advanced to the IND application preparation stage.

Impact on Investors and Future Outlook

Cullgen's latest development progress demonstrates strengthening of its pipeline, with upcoming clinical trial initiation expected to drive tangible progress towards commercialization. Participation in the J.P. Morgan Healthcare Conference provides an important platform for information dissemination to global investors and industry stakeholders, enhancing opportunities for fundraising and partnerships. These developments may contribute significantly to the business growth of GNI Corporation, making them noteworthy for investors.